SZShahriar A. Zamani

Shahriar A. Zamani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shahriar A. Zamani has a total of 81 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers
    Open Access

    Integrated epidemiological and molecular data inform the relationship between precancer and cancer states of esophageal adenocarcinoma

    by Shahriar A. Zamani, Lianlian Wu, Emily L. Black, Alexander Bartram, Alvin W. T. Ng, Maria Secrier, Jacqueline D. Perelman, Ahsen Ustaoglu, Emma Ococks, Daniel Jacobson, et al.

    Cancer generally takes years to evolve, and early diagnosis can prevent life-threatening cancer. Establishing a link between precancerous states and cancer is essential for effective screening and prevention. Esophageal adenocarcinoma (EAC) is an increasingly prevalent, poor-outcome cancer, and its presumed precursor, Barrett’s esophagus (BE), characterized by intestinal metaplasia, is evident in only about half of cases. Here to test whether BE is a prerequisite to EAC, we integrated epidemiological and clinical characteristics in a prospective cohort of 3,100 patients with EAC for any evidence of BE (BE-positive and BE-negative) and compared genomic features using a subset of 710 patients with whole-genome sequencing and 87 patients (380 samples) with multiregional whole-exome sequencing. Demographic and genomic features typically associated with BE were observed across BE-positive and BE-negative EAC cases. Notably, molecular features consistent with early BE evolution were detected in both phenotypes. Advanced tumor stage was the only variable that corresponded with increased likelihood of BE-negative EAC, including in some patients with a previous BE diagnosis. Phylogenetic analyses revealed shared evolutionary trajectories, and spatial transcriptomic and proteomic analyses demonstrated intestinal metaplasia-associated lineage markers in both groups. These findings suggest a single pathway to EAC, with implications for early diagnosis and prevention strategies.


  • Homologous recombination repair germline variants and subsequent neoplasm risk among childhood cancer survivors

    by Shahriar A Zamani, Danielle M Karyadi, Stephen W Hartley, Todd M Gibson, Joshua N Sampson, Peter Kraft, Stephen J Chanock, Lindsay M Morton

    Childhood cancer radiation therapy (RT) increases subsequent neoplasm risk. Radiation dose may modulate DNA damage responses, but the small sample sizes of prior human studies of homologous recombination repair hampered dose-specific investigations. We pooled data for 12 180 survivors (8339 from the Childhood Cancer Survivor Study and 3841 from the St Jude Lifetime Cohort) to estimate associations between deleterious homologous recombination repair variants and RT-related subsequent neoplasms (most commonly breast cancer, meningioma, thyroid cancer, and sarcoma) using conditional logistic regression with matched controls. In all, 1253 (10.3%) survivors were homologous recombination repair variant carriers, and 1301 (10.7%) developed at least 1 RT-related subsequent neoplasms. Variants increased the risk of out-of-field RT-related subsequent neoplasms (cases, 40/190 [21.1%]; control individuals, 9.7%; odds ratio [OR] = 2.5, 95% confidence interval [CI] = 1.7 to 3.6; P = 4.80 ×10−6), with consistent results across cohorts (Childhood Cancer Survivor Study, OR = 2.5, 95% CI = 1.6 to 3.7, P = 3.77 ×10−5; St Jude Lifetime Cohort, OR = 2.5, 95% CI = 1.0 to 6.4, P = 3.07 ×10−2). No association was observed for in-field or near-field subsequent neoplasms or individuals not undergoing RT. Findings emphasize homologous recombination repair variant-conferred susceptibility to RT-related subsequent neoplasms and dose-dependent DNA damage repair.

  • Germline rare variants in cancer susceptibility genes and subsequent neoplasm risk after childhood cancer

    by Shahriar A Zamani, Danielle M Karyadi, Stephen W Hartley, Todd M Gibson, Joshua N Sampson, Peter Kraft, Stephen J Chanock, Lindsay M Morton

    Background: Among childhood cancer survivors, germline rare variants in autosomal dominant cancer susceptibility genes could increase the risk of subsequent neoplasms, but risks for rarer subsequent neoplasms and by age at onset are not well understood. Methods: We pooled the Childhood Cancer Survivor Study and St Jude Lifetime Cohort (median follow-up = 29.7 years [range = 7.1-55.6 years]) to identify rare deleterious germline variants across 150 literature-based cancer susceptibility genes using the ClinVar (National Library of Medicine) and SnpEff tools. Conditional logistic regression evaluated overall and subsequent neoplasm–specific risk, matching up to 100 subsequent neoplasm–free control individuals to participants by age, sex, childhood cancer type, radiation dose, chemotherapy, study, and follow-up time. Results: Among 11 840 survivors, 2165 (18.3%) developed 1 or more subsequent neoplasms. Overall subsequent neoplasm risk was modestly increased for variant carriers in any autosomal dominant cancer susceptibility gene (288/2165 [13.3%] cases; 9.9% of control individuals; odds ratio [OR] = 1.4, 95% CI = 1.3 to 1.6; P = 5.0 × 10−7). Carriers of variants in cancer-specific autosomal dominant cancer susceptibility genes had higher subsequent neoplasm risks, particularly for glioma (OR = 20.4, 95% CI = 7.4 to 56.1; P = 2.7 × 10−10), colorectal cancer (OR = 5.9, 95% CI = 1.4 to 25.7; P = 9.1 × 10−3), bone/soft-tissue sarcoma (OR = 5.3, 95% CI = 2.2 to 12.7; P = 1.5 × 10−3), meningioma (OR = 4.0, 95% CI = 1.4 to 1.0; P = 3.2 × 10−3), basal cell carcinoma (OR = 3.5, 95% CI = 1.2 to 10.0; P = .020), and breast cancer (OR = 2.6, 95% CI = 1.8 to 3.9; P = 2.8 × 10−6), who were also more likely to develop such subsequent neoplasms at younger ages. Notably, all meningioma, sarcoma, and glioma subsequent neoplasms among carriers occurred before ages 20, 25, and 35 years, respectively. Conclusions: Survivors with rare germline variants in cancer-specific autosomal dominant cancer susceptibility genes had increased subsequent neoplasm risk, especially at younger ages. These findings offer a potential basis for enhancing risk-stratified long-term surveillance for childhood cancer survivors.


  • Open Access

    Integrated epidemiogical and genomic data yields insights into the relationship between precancer and cancer states of the oesophagus

    by Rebecca Fitzgerald, Shahriar Zamani, Lianlian Wu, Emily Black, Alex Bartram, Alvin Wei Tian Ng, Maria Secrier, Daniel Jacobson, Ginny Devonshire, Nicola Grehan, et al.

    Cancer generally takes years to evolve, and early diagnosis can prevent life-threatening cancer 1,2 . Symptomatic, advanced cancers often lack evidence of a precancer at diagnosis and yet, if the link between a precancerous state and cancer can be proven, the opportunity arises for screening and prevention. Oesophageal adenocarcinoma (EAC) is an increasingly prevalent, 3 poor outcome cancer and its presumed precursor, Barrett’s oesophagus (BE) is only evident in around half of cases 4,5 . To test the hypothesis that BE is not a pre-requisite to EAC we classified a prospective cohort of 3,100 EAC patients for any evidence of BE and compared the epidemiological, clinical and genomic characteristics. Our findings demonstrate that there are specific demographic and genomic features observed in BE that also correlate strongly with EAC, regardless of the presence of a BE phenotype. Further we found evidence for the earliest features of BE evolution in both BE-negative and BE-positive EAC phenotypes. Advanced tumour stage was the only variable that corresponded with increased likelihood of BE-negative EAC, including in some patients with a prior diagnosis of Barrett’s. The role of a single BE-mediated pathway to EAC has implications for early diagnosis strategies. We anticipate that our methodology combining large epidemiological and genomic datasets with respect to phenotype could help establish the significance of other precancer states.

  • Open Access

    Use of cholesterol‐lowering medications in relation to risk of primary liver cancer in the Clinical Practice Research Datalink

    by Shahriar A. Zamani, Barry I. Graubard, Marianne Hyer, Emily Carver, Jessica L. Petrick, Katherine A. McGlynn

    Background: Although the relation between statin use and liver cancer risk has been extensively examined, few studies have examined other cholesterol‐lowering medications in relation to liver cancer risk. The authors examined five classes of nonstatin medications and liver cancer risk.Methods: A nested case–control including 3719 cases and 14,876 matched controls was conducted within the Clinical Practice Research Datalink. Additional matches on type 2 diabetes and chronic liver disease were also implemented. The medications examined included cholesterol absorption inhibitors, bile acid sequestrants, fibrates, niacin, and omega‐3 fatty acids. Conditional logistic regression estimated odds ratios and 95% confidence intervals.Results: Cholesterol absorption inhibitor use was associated with reduced liver cancer risk in the overall analysis (odds ratio, 0.69; 95% confidence interval, 0.50–0.96) and in analyses based on type 2 diabetes and chronic liver disease status. Although bile acid sequestrant use was associated with increased liver cancer risk in the overall analysis (odds ratio, 5.31; 95% confidence interval, 3.53–7.97), the results of the analyses based on type 2 diabetes and chronic liver disease status were inconsistent. [Correction added on 19 August 2024, after first online publication: In the preceding sentence, the value ‘3.534’ has been changed to ‘3.54’.]. No associations were observed for the other medications.Conclusions: Cholesterol absorption inhibitors may be associated with reduced liver cancer risk. Whether bile acid sequestrant use was associated with increased risk was only partially supported in the current study.


  • Open Access

    Author Correction: Disentangling oncogenic amplicons in esophageal adenocarcinoma

    by Alvin Wei Tian Ng, Dylan Peter McClurg, Ben Wesley, Shahriar A. Zamani, Emily Black, Ahmad Miremadi, Olivier Giger, Rogier Ten Hoopen, Ginny Devonshire, Aisling M. Redmond, et al.


  • Open Access

    Disentangling oncogenic amplicons in esophageal adenocarcinoma

    by Alvin Wei Tian Ng, Dylan Peter McClurg, Ben Wesley, Shahriar A. Zamani, Emily Black, Ahmad Miremadi, Olivier Giger, Rogier Ten Hoopen, Ginny Devonshire, Aisling M. Redmond, et al.

    Esophageal adenocarcinoma is a prominent example of cancer characterized by frequent amplifications in oncogenes. However, the mechanisms leading to amplicons that involve breakage-fusion-bridge cycles and extrachromosomal DNA are poorly understood. Here, we use 710 esophageal adenocarcinoma cases with matched samples and patient-derived organoids to disentangle complex amplicons and their associated mechanisms. Short-read sequencing identifies ERBB2, MYC, MDM2, and HMGA2 as the most frequent oncogenes amplified in extrachromosomal DNAs. We resolve complex extrachromosomal DNA and breakage-fusion-bridge cycles amplicons by integrating of de-novo assemblies and DNA methylation in nine long-read sequenced cases. Complex amplicons shared between precancerous biopsy and late-stage tumor, an enrichment of putative enhancer elements and mobile element insertions are potential drivers of complex amplicons’ origin. We find that patient-derived organoids recapitulate extrachromosomal DNA observed in the primary tumors and single-cell DNA sequencing capture extrachromosomal DNA-driven clonal dynamics across passages. Prospectively, long-read and single-cell DNA sequencing technologies can lead to better prediction of clonal evolution in esophageal adenocarcinoma.


  • A decade of the Oesophageal Cancer Clinical and Molecular Stratification Consortium

    by C. J. Peters, Y. Ang, F. D. Ciccarelli, H. Coles, H. G. Coleman, G. Contino, T. Crosby, G. Devonshire, M. Eldridge, A. Freeman, et al.


  • Open Access

    Mutational signature dynamics shaping the evolution of oesophageal adenocarcinoma

    by Sujath Abbas, Oriol Pich, Ginny Devonshire, Shahriar A. Zamani, Annalise Katz-Summercorn, Sarah Killcoyne, Calvin Cheah, Barbara Nutzinger, Nicola Grehan, Nuria Lopez-Bigas, et al.

    A variety of mutational processes drive cancer development, but their dynamics across the entire disease spectrum from pre-cancerous to advanced neoplasia are poorly understood. We explore the mutagenic processes shaping oesophageal adenocarcinoma tumorigenesis in 997 instances comprising distinct stages of this malignancy, from Barrett Oesophagus to primary tumours and advanced metastatic disease. The mutational landscape is dominated by the C[T > C/G]T substitution enriched signatures SBS17a/b, which are linked withTP53mutations, increased proliferation, genomic instability and disease progression. The APOBEC mutagenesis signature is a weak but persistent signal amplified in primary tumours. We also identify prevalent alterations in DNA damage repair pathways, with homologous recombination, base and nucleotide excision repair and translesion synthesis mutated in up to 50% of the cohort, and surprisingly uncoupled from transcriptional activity. Among these, the presence of base excision repair deficiencies show remarkably poor prognosis in the cohort. In this work, we provide insights on the mutational aetiology and changes enabling the transition from pre-neoplastic to advanced oesophageal adenocarcinoma.


  • A Mixed-Methods Assessment of a Peer-Enforced Tobacco- and Smoke-Free Policy at a Large Urban University

    by Amy Gatto, Sarah E. Powell, Emily F. Walters, Shahriar Zamani, Liberty B. Sales, Rita DeBate

    The study aims to evaluate the enforcement, opinions, and effectiveness of the University of South Florida’s tobacco free policy one year following implementation. By assessing readiness to change and using geographic information system (GIS) mapping this study sought to introduce a unique and effective way of evaluating college tobacco free policies. A cross-sectional survey was administered to students, faculty, and staff to assess knowledge of policy and resources, tobacco use observations, stage change regarding policy enforcement, self-efficacy to enforce, and policy impact on perceived campus tobacco use (n = 5242). Additionally, using ArcGIS Collector (in: ESRI, ArcGIS desktop: release 10, Environmental Systems Research Institute, Redlands, 2011) volunteers collected geospatial data on tobacco use continuing to occur on campus following policy implementation. Overall there was moderate knowledge of the current policy and low beliefs for policy enforcement. Majority of respondents were not approaching violators to remind them of the policy and did not plan to do so in the future. There were statistically significant differences between smokers and non-smokers as well as between students and faculty and staff. The mapping of observed violations revealed continued tobacco use on campus with 158 data points. From both the geospatial results as well as the survey findings, the current policy is ineffective in reducing tobacco use across campus. With rapidly increasing numbers of smoke and tobacco free universities, new and innovative evaluation tools are needed so institution leaders can efficiently evaluate their implementation.